

BC Cancer Protocol Summary for Treatment of Oral Mucositis Using BC Cancer Magic Mouthwash

Protocol Code

SCMMW

Tumour Group

Supportive Care

Contact Pharmacist

Lisa Wanbon (VIC)

ELIGIBILITY:

- Patients with diagnosis of oral mucositis caused by systemic anti-cancer therapy.
- Drug acquisition: Magic mouthwash is considered a supportive treatment. It is not a BC Cancer benefit drug. Patients should fill their magic mouthwash prescription at a community pharmacy. It is covered [as a BC PharmaCare Limited Coverage Benefit subject to usual PharmaCare rules and deductibles as well as the PharmaCare Compounded Prescription Pricing Policy \(5.13\)](#). Physicians who currently have Special Authority exemption for ondansetron have received an exemption from the Special Authority process for BC Cancer Magic Mouthwash under the Product Identification Number 22123334. No Special Authority application needs to be submitted for this compound.

EXCLUSION:

- Prevention of oral mucositis

TREATMENT:

Drug	Dose	BC Cancer Administration Guideline
diphenhydrAMINE liquid (12.5 mg/5 mL)	300 mL	20 mL swish and spit every 4-6 hours PRN
hydrocortisone injection (100 mg/2 mL)	2 mL	
nystatin suspension (100,000 units/mL)	100 mL	or
distilled water	qs 1000 mL	20 mL swish and swallow every 4-6 hours PRN

Repeat treatment as needed.

EVIDENCE REVIEW:

1. There is no standard formulation for magic mouthwash. Guidelines from the European Society for Medical Oncology (ESMO) 2015, Multinational Association of Supportive Care in Cancer (MASCC) 2014, and National Comprehensive Cancer Network (NCCN) 2008 have no recommendation for magic mouthwash ingredients due to insufficient evidence.
2. BC Cancer Magic Mouthwash formulation incorporates historically used ingredients:

Drug	Purpose	Evidence
diphenhydrAMINE	analgesic	<ul style="list-style-type: none"> efficacy and safety as an ingredient in magic mouthwash have been shown
hydrocortisone	anti-inflammatory	<ul style="list-style-type: none"> efficacy and safety not adequately studied use suggested per expert opinions
nystatin	antifungal	<ul style="list-style-type: none"> efficacy and safety not adequately studied use likely needed when a steroid is used per expert opinions

3. **Expiry and Storage:** There is no stability data available for extemporaneously prepared diphenhydrAMINE-hydrocortisone-nystatin mixture. In the absence of stability data that is applicable to a specific non-sterile compounded preparation, the National Association of Pharmacy Regulatory Authorities (NAPRA) recommends a beyond-use date to be not later than 14 days with storage at controlled cold temperatures.

PRECAUTION:

1. **Drowsiness:** unlikely with the diphenhydrAMINE amounts used in BC Cancer Magic Mouthwash if preparation is for swishing and spitting. Higher concentrations of diphenhydrAMINE have been used in other magic mouthwash formulations with no significant drowsiness compared to placebo. If preparation is for swishing and swallowing, drowsiness may result.

Call tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

References:

- Allan Hovan, DMD. Personal communication. BC Cancer Dentistry; 19 September 2018.
- Bensinger W, Schubert M, Ang K, et al. NCCN Task Force Report: prevention and management of mucositis in cancer care. J Natl Compr Canc Netw 2008;6 Suppl 1:S1-21.
- Chan A, Ignoffo RJ. Survey of topical oral solutions for the treatment of chemo-induced oral mucositis. J Oncol Pharm Pract 2005;11(4):139-43.
- Cheryl Ho, MD. Personal communication. BC Cancer Medical Oncology; 1 August 2018.
- Frances Wong, MD. Personal communication. BC Cancer Radiation Oncology; 2 August 2018.
- Harris DJ, Eilers J, Harriman A, et al. Putting evidence into practice: evidence-based interventions for the management of oral mucositis. Clin J Oncol Nurs 2014;12(1):141-52.
- Jeffrey Curtis, RPh. Personal communication. Macdonald's Pharmacy. 1 August 2018.
- Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014;120(10):1453-61.
- McGuire DB, Fulton JS, Park J, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 2013;21(11):3165-77.
- National Association of Pharmacy Regulatory Authorities. Guidance Document for Pharmacy Compounding of Non-Sterile Preparations. Ottawa, Ontario: NAPRA; 28 Mar 2018.

11. Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. *Support Care Cancer* 2013;21(11):3179-89.
12. Peterson DE, Boers-Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. *Ann Oncol* 2015;26 Suppl 5:v139-51.
13. Pippa Hawley, MD. Personal communication. BC Cancer Pain & Symptom Management/Palliative Care; 31 July 2018.
14. Sio TT, Le-Rademacher JG, Leenstra JL, et al. Effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo on radiotherapy-related oral mucositis pain. *JAMA* 2019;321(15):1481-90.
15. The United States Pharmacopeia. General Chapter 795: Pharmaceutical compounding – nonsterile preparations. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 1 May 2018.